DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Fillit - 1 Eli Lilly's Alzheimer's - 1 Howard Fillit - 1 Eli Lilly's - 1
Top related locs:
Top related orgs:
Discovery Foundation - 1 FDA - 1

Search resuls for: "Fillit"


2 mentions found


☆ Dr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs & success for the first time
  + stars: | 2024-06-11 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs & success for the first timeDr. Howard Fillit, Alzheimer’s Drug Discovery Foundation co-founder and chief science officer, joins 'Squawk Box' to discuss news of FDA panel's approval of Eli Lilly's Alzheimer's drug Donanemab, the future of Alzheimer's treatments, and more.
Persons: Fillit, Eli Lilly's Alzheimer's, Howard Fillit, Eli Lilly's Organizations: Discovery Foundation, FDA
☆ Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focus
  + stars: | 2022-11-30 | by ( Deena Beasley | ) www.reuters.com   time to read: +5 min
The drug, lecanemab, was associated with a type of brain swelling in 12.6% of trial patients, a side effect previously seen with similar drugs. He suggested that could be because homozygous study patients who were given a placebo fared better than expected. Overall, lecanemab patients benefited by 23% to 26% compared with a placebo on these secondary trial goals. Detailed data from the study were presented at the Clinical Trials on Alzheimer's Disease meeting in San Francisco and published in the New England Journal of Medicine. Dr. Howard Fillit, chief science officer at the Alzheimer’s Drug Discovery Foundation, said doctors always balance the benefits and risks of therapies.
0 next >>
Total: 2